Patent Assignment
Reel/Frame 036126/0359
Merger
Recorded: 2015-07-16
Pages: 9
Assignor
OXFORD AMHERST CORPORATION
Executed: 2015-05-26
Assignee
PHARMACYCLICS, INC.
995 EAST ARQUES AVENUE, SUNNYVALE, CALIFORNIA, 94085
Covered Properties
(116)
Method of Using Histone Deacetylase Inhibitors and Monitoring Biomarkers in Combination Therapy
Methods for Determining Cancer Resistance to Histone Deacetylase Inhibitors
Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Application:
13/003,811 →
Publication:
US US20110224235A1
Methods of Treating Abc-Dlbcl Using Inhibitors of Bruton's Tyrosine Kinase
Application:
13/153,291 →
Publication:
US US20120071497A1
Treatment of Blood Cell Malignancies with Intracellular Kinase Inhibitors
Application:
13/177,657 →
Publication:
US US20110281850A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/232,784 →
Publication:
US US20120065201A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/340,559 →
Publication:
US US20120101113A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/340,621 →
Publication:
US US20120101114A1
Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Inhibitors of B Lymphocyte Kinase
Application:
13/404,422 →
Publication:
US US20120165328A1
Inhibitors of BMX non-receptor tyrosine kinase
Application:
13/410,110 →
Publication:
US US20120184013A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/430,173 →
Publication:
US US20120184567A1
Inhibitors of IL2-Inducible T-Cell Kinase
Application:
13/439,775 →
Publication:
US US20120202264A1
Methods and Compositions for Inhibition of Bone Resorption
Application:
13/536,799 →
Publication:
US US20130178483A1
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/543,399 →
Publication:
US US20120296089A1
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/607,036 →
Publication:
US US20120329130A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/612,143 →
Publication:
US US20130018060A1
PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
Bruton's Tyrosinie Kinase Activity Probe and Method of Using
Application:
13/856,380 →
Publication:
US US20130225812A1
Inhibitors of Bruton's Tyrosine Kinase
Crystalline Forms of a Bruton's Tyrosine Kinase Inhibitor
Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Inhibitors of Bruton's Tyrosine Kinase
Manufacture, Compositions and Uses of Coagulation Factor Viia Modulator
Application:
14/049,143 →
Publication:
US US20140039022A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
14/069,222 →
Publication:
US US20140057907A1
Formulations of Histone Deacetylase Inhibitor and Uses Therof
Tec Family Kinase Inhibitor Adjuvant Therapy
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Intracellular Kinase Inhibitors
Application:
14/076,457 →
Publication:
US US20140080833A1
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Pyrrolopyrimidine Compounds as Kinase Inhibitors
Inhibitors of Bruton's Tyrosine Kinase
Application:
14/085,722 →
Publication:
US US20140080844A1
Association Between N-Hydroxy-4-{2-[3-(N,N-Dimethylaminomethyl)Benzofuran-2-Ylcarbonylamino]Ethoxy}Benzamide and Folfox
Application:
14/130,134 →
Publication:
US US20150038513A1
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Application:
14/179,457 →
Publication:
US US20140163027A1
New Salt of Abexinostat, Associated Crystalline Form, a Process for Their Preparation and Pharmaceutical Compositions Containing Them
Tec Family Kinase Inhibitor Adjuvant Therapy
Application:
14/198,559 →
Publication:
US US20140371241A1
Factor Viia Inhibitor
2-(2-Hydroxybiphenyl-3-Yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor Viia Inhibitors
Crystalline Forms of a Bruton's Tyrosine Kinase Inhibitor
Application:
14/339,363 →
Publication:
US US20140336203A1
Inhibitors of Bruton's Tyrosine Kinase
Formulations of Histone Deacetylase Inhibitor in Combination with Bendamustine and Uses Thereof
Use of Inhibitors of Bruton's Tyrosine Kinase (Btk)
Application:
14/353,011 →
Publication:
US US20140303191A1
Cinnamic Acid Hydroxyamides as Inhibitors of Histone Deacetylase 8
Application:
14/368,475 →
Publication:
US US20150045367A1
PYRAZOLO[3,4-d]PYRIMIDINE AND PYRAZOLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
Purinone Compounds as Kinase Inhibitors
Combinations of Histone Deacetylase Inhibitor and Pazopanib and Uses Thereof
Application:
14/377,380 →
Publication:
US US20150335609A1
Inhibitors of Bruton's Tyrosine Kinase
Crystalline Forms of a Bruton's Tyrosine Kinase Inhibitor
Mutations Associated with Resistance to Inhibitors of Bruton's Tyrosine Kinase (Btk)
Companion Diagnostics for Tec Family Kinase Inhibitor Therapy
Application:
14/434,015 →
Publication:
US US20150260723A1
Methods for the Treatment of Solid Tumors
Methods for the Treatment of HER2 Amplified Cancer
Inhibitors of Bruton's Tyrosine Kinase
Administration Regime for N-Hydroxy-4-{2-[3-(N,N-Dimethylaminomethyl) Benzofuran-2-Ylcarbonylamino]Ethoxy}Benzamide
Application:
14/510,369 →
Publication:
US US20150024040A1
Selective Inhibitors of Histone Deactylase
Application:
14/521,377 →
Publication:
US US20150320758A1
Uses of Selective Inhibitors of HDAC8 and Treatment of Inflammatory Conditions
Application:
14/521,383 →
Publication:
US US20150038542A1
Methods of Treating and Preventing Graft Versus Host Disease
Treatment Using Bruton's Tyrosine Kinase Inhibitors and Immunotherapy
Application:
14/523,782 →
Publication:
US US20150118222A1
Indole Derivatives as Inhibitors of Histone Deacetylase
Methods for Delaying or Preventing the Onset of Type 1 Diabetes
Application:
14/542,458 →
Publication:
US US20150141438A1
Methods of Treating and Preventing Alloantibody Driven Chronic Graft Versus Host Disease
Application:
14/558,297 →
Publication:
US US20150157634A1
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Inhibitors of Bruton's Tyrosine Kinase
Application:
14/605,857 →
Publication:
US US20150265618A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
14/613,309 →
Publication:
US US20150306103A1
Inhibitors of Bruton's Tyrosine Kinase
Application:
14/613,313 →
Publication:
US US20150152115A1
Formulations of Histone Deacetylase Inhibitor and Uses Therof
Application:
14/620,075 →
Publication:
US US20150164854A1
Biomarkers for Predicting Response of Dlbcl to Treatment with Ibrutinib
Application:
14/628,112 →
Publication:
US US20150238490A1
Phospholipase C Gamma 2 and Resistance Associated Mutations
Novel Hydroxamates as Therapeutic Agents
Inhibitors of Bruton's Tyrosine Kinase
Application:
14/703,750 →
Publication:
US US20150307500A1
Pyrrolopyrimidine Compounds as Kinase Inhibitors
Hdac Inhibitor and Btk Inhibitor Combinations
Application:
14/731,173 →
Publication:
US US20150352116A1
Biomarker for Predicting Response of Cll to Treatment with a Btk Inhibitor
Application:
14/738,617 →
Publication:
US US20150361504A1
Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Crystalline Forms of the Abexinostat Salt, a Process for Its Preparation and Pharmaceutical Compositions Containing It
Application:
61/772,191 →
Ibrutinib Combination Therapy
Application:
61/809,810 →
Purinone Compounds as Kinase Inhibitors
Application:
61/842,321 →
Methods of Treating and Preventing Graft Versus Host Disease
Application:
61/910,945 →
Treatment Using Bruton's Tyrosine Kinase Inhibitors and Immunotherapy
Application:
61/968,312 →
Methods for the Treatment of HER2 Amplified Cancer
Application:
61/969,003 →
Methods of Treating and Preventing Graft Versus Host Disease
Application:
61/973,173 →
Methods of Treating and Preventing Graft Versus Host Disease
Application:
61/973,176 →
Hdac Inhibitor and Btk Inhibitor Combinations
Application:
62/007,696 →
Treatment Using Bruton's Tyrosine Kinase (Btk) Inhibitors and Immunotherapy
Application:
62/023,705 →
Treatment Using Bruton's Tyrosine Kinase Inhibitors and Immunotherapy
Application:
62/023,742 →
Btk Inhibitors for the Treatment of Cns Malignancies
Application:
62/024,457 →
Bet Inhibitor and Bruton's Tyrosine Kinase Inhibitor Combinations
Application:
62/029,346 →
Btk Inhibitors for the Treatment of Cns Malignancies
Application:
62/030,023 →
Biomarkers for Predicting Response of Dlbcl to Treatment with a Btk Inhibitor
Application:
62/032,430 →
Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
Application:
62/034,353 →
Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof
Application:
62/034,997 →
Methods for Treating Egfr Mutant Disorders
Application:
62/040,390 →
Dendritic Cell Based Vaccine with Bruton's Tyrosine Kinase Inhibitor
Application:
62/052,361 →
Btk Inhibitors for the Treatment of Cns Malignancies
Application:
62/052,394 →
Tlr Inhibitor and Bruton's Tyrosine Kinase Inhibitor Combinations
Application:
62/080,921 →
Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof
Application:
62/082,972 →
Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof
Application:
62/086,162 →
Methods of Treating Fibrosis
Application:
62/086,945 →
Btk Inhibitor Combinations and Dosing Regimen
Application:
62/096,284 →
Synthesis of a Bruton's Tyrosine Kinase Inhibitor
Application:
62/103,507 →
Btk Inhibitor Combinations and Multidrug-Resistance
Application:
62/110,301 →
Biomarkers for Predicting Response of Dlbcl to Treatment with a Btk Inhibitor
Application:
62/119,668 →
Biomarkers for Predicting Response of Dlbcl to Treatment with a Btk Inhibitor
Application:
62/127,484 →
Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor
Application:
62/127,717 →
Tlr Inhibitor and Bruton's Tyrosine Kinase Inhibitor Combinations
Application:
62/127,740 →
Solvated Forms of a Bruton's Tyrosinse Kinase Inhibitor
Application:
62/139,594 →
Co-Crystals of a Bruton's Tyrosine Kinase Inhibitor
Application:
62/139,599 →
Combinations for Generating Tumor-Specific Immunological Memory
Application:
62/142,961 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Feb 12, 2008
From: ADIMOOLAM, SHANTHI; BUGGY, JOSEPH J.; MAGDA, DARREN; MILLER, RICHARD
To: PHARMACYCLICS, INC.
Reel/Frame 020499/0460 →
Assignment of Assignor's Interest
Nov 29, 2010
From: BUGGY, JOSEPH J.; BALASUBRAMANIAN, SRIRAM
To: PHARMACYCLICS, INC.
Reel/Frame 025428/0233 →
Assignment of Assignor's Interest
May 25, 2011
From: HONIGBERG, LEE; VERNER, ERIK; BUGGY, JOSEPH; LOURY, DAVID
To: PHARMACYCLICS, INC.
Reel/Frame 026339/0401 →
Assignment of Assignor's Interest
Jul 12, 2011
From: FLYNN, GARY A.; LEE, SANDRA AEYOUNG; FARIS, MARY; BRANDT, DAVID WILLIAM
To: MANNKIND CORPORATION
Reel/Frame 026575/0598 →
Assignment of Assignor's Interest
Sep 14, 2011
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 026905/0378 →
Assignment of Assignor's Interest
Jan 3, 2012
From: BUGGY, JOSEPH J.; STAUDT, LOUIS MICHAEL; WILSON, WYNDHAM HOPKINS
To: PHARMACYCLICS, INC.
Reel/Frame 027471/0762 →
Assignment of Assignor's Interest
Jan 3, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 027471/0268 →
Assignment of Assignor's Interest
Jan 3, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 027471/0255 →
Assignment of Assignor's Interest
Feb 7, 2012
From: HONIGBERG, LEE; VERNER, ERIK; BUGGY, JOSEPH; LOURY, DAVID
To: PHARMACYCLICS, INC.
Reel/Frame 027666/0607 →
Assignment of Assignor's Interest
Feb 24, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 027759/0062 →
Assignment of Assignor's Interest
Mar 6, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 027811/0593 →
Assignment of Assignor's Interest
Mar 29, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 027954/0636 →
Assignment of Assignor's Interest
Apr 6, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 028005/0425 →
Assignment of Assignor's Interest
Jul 6, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 028502/0855 →
Assignment of Assignor's Interest
Jul 31, 2012
From: CHEN, WEI; LOURY, DAVID J.; MODY, TARAK D.; WANG, LONGCHENG
To: PHARMACYCLICS, INC.
Reel/Frame 028685/0804 →
Assignment of Assignor's Interest
Sep 7, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 028921/0087 →
Assignment of Assignor's Interest
Sep 10, 2012
From: BUGGY, JOSEPH J.; CHANG, BETTY Y.
To: PHARMACYCLICS, INC.
Reel/Frame 028928/0487 →
Assignment of Assignor's Interest
Sep 21, 2012
From: CHEN, WEI; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 029006/0828 →
Assignment of Assignor's Interest
Sep 21, 2012
From: HONIGBERG, LEE; VERNER, ERIK J.; BUGGY, JOSEPH J.; LOURY, DAVID J.
To: PHARMACYCLICS, INC.
Reel/Frame 029006/0789 →
Assignment of Assignor's Interest
Oct 12, 2012
From: MODY, TARAK D.
To: PHARMACYCLICS, INC.
Reel/Frame 029217/0111 →
Assignment of Assignor's Interest
Aug 4, 2014
From: MANNKIND CORPORATION
To: PHARMACYCLICS INC.
Reel/Frame 033454/0968 →
Assignment of Assignor's Interest
Feb 19, 2015
From: HONIGBERG, LEE; VERNER, ERIK; PAN, ZHENGYING
To: PHARMACYCLICS, INC.
Reel/Frame 034982/0405 →
Merger and Change of Name
Jul 16, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036126/0368 →
Merger and Change of Name
Jul 18, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036130/0104 →
Merger
Jul 18, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036130/0098 →